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Background: Hyperglycemia in pregnancy (HIP) is a common medical 
complication during pregnancy and is associated with several short 
and long-term maternal-fetal consequences. We aimed to determine 
the prevalence and factors associated with HIP among Ugandan 
women. 
Methods: We consecutively enrolled eligible pregnant women 
attending antenatal care at Kawempe National Referral Hospital, 
Kampala, Uganda in September 2020. Mothers known to be living with 
diabetes mellitus or haemoglobinopathies and those with anemia 
(hemoglobin <11g/dl) were excluded. Random blood sugar (RBS) and 
glycated hemoglobin A1c (HbA1c) were measured on peripheral 
venous blood samples. HIP was defined as an HbA1c ≥5.7% with its 
subsets of diabetes in pregnancy (DIP) and prediabetes defined as 
HbA1c of ≥6.5% and 5.7-6.4% respectively. ROC curve analysis was 
performed to determine the optimum cutoff of RBS to screen for HIP. 
Results: A total of 224 mothers with a mean (± SD) age 26±5 years 
were enrolled, most of whom were in the 2nd or 3rd trimester (94.6%, 
n=212) with a mean gestation age of 26.6±7.3 weeks. Prevalence of 
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HIP was 11.2% (n=25) (95% CI: 7.7-16.0). Among the mothers with HIP, 
2.2% (n=5) had DIP and 8.9% (n=20) prediabetes. Patients with HIP 
were older (28 years vs. 26 years, p=0.027), had previous tuberculosis 
(TB) contact (24% vs. 6.5%, p=0.003) and had a bigger hip 
circumference (107.8 (±10.4) vs. 103.3 (±9.7) cm, p = 0.032). However 
only previous TB contact was predictive of HIP (odds ratio: 4.4, 95% CI: 
1.2-14.0; p=0.022). Using HbA1c as a reference variable, we derived an 
optimum RBS cutoff of 4.75 mmol/L as predictive of HIP with a 
sensitivity and specificity of 90.7% and 56.4% (area under the curve = 
0.75 (95% CI: 0.70-0.80, p<0.001)), respectively. 
Conclusions: HIP is common among young Ugandan women, the 
majority of whom are without identifiable risk factors.
Keywords 
Hyperglycemia in pregnancy, prediabetes, Hemoglobin A1c, Uganda
 




Page 2 of 10
Emerald Open Research 2020, 2:70 Last updated: 15 DEC 2020
Introduction
Pregnancy is naturally characterized by insulin resistance and 
hyperinsulinemia leading to hyperglycemia, the most common 
endocrinopathy during the gestation period (Farrar, 2016; 
Saravanan et al., 2020). Previously, any hyperglycemia detected 
in pregnancy was termed gestational diabetes (GDM) (WHO, 
2013). However, recently, the term hyperglycemia in pregnancy 
(HIP) has been proposed by the World Health Organization 
(WHO) (Diabetes Canada Clinical Practice Guidelines Expert 
Committee et al., 2018; WHO, 2018). HIP classifies hyperg-
lycemia based on both onset and severity (Diabetes Canada 
Clinical Practice Guidelines Expert Committee et al., 2018; 
WHO, 2018). It includes the more severe manifestations of total 
diabetes in pregnancy (comprising of known and previously 
undiagnosed diabetes in pregnancy [DIP]), which may persist 
in the post-partum period and a more benign form, GDM 
(WHO, 2013). DIP and GDM are together termed hyperglycemia 
first detected in pregnancy (WHO, 2013).
HIP is a growing public health concern and adversely affects 
maternal and child health, and is likely to contribute to the 
growing global diabetes epidemic (Bianco & Josefson 2019; 
Guariguata et al., 2014). Depending on the diagnostic criteria 
used and the population of pregnant women studied, the resulting 
prevalence of HIP can vary widely. Results from a recent survey 
on HIP prevalence in 173 countries found country-specific 
prevalence estimates ranging from <1% in Germany up to 28% 
for a study in Nepal, using a variety of criteria (Jiwani et al., 
2012). Globally, HIP has been estimated to affect nearly 16.9%, 
or 21.4 million, live births among women of reproductive age, 
with total diabetes in pregnancy accounting for an estimated 
16.0% of these cases (Guariguata et al., 2014). In this report, 
more than 90% of cases of HIP were estimated to occur in 
low- and middle-income countries (LMICs), with South-East 
Asian and African regions having the highest number of live 
births affected with HIP at over 6.0 (23.2%) and 4.3 (16.0%) 
million cases, respectively (Guariguata et al., 2014).
Previous studies assessing the prevalence of HIP have mostly 
concentrated on high risk mothers, such as those with advanced 
age, high gravidity or in a specific period of gestation age, which 
may not reflect the true prevalence in the general population of 
pregnant women (Adefisan et al., 2020; Cosson et al., 2019; 
Mukuve et al., 2020). Moreover, screening and intervention on 
HIP during antenatal care (ANC) are not routine in most 
LMICs, making an accurate estimation of the burden of this 
treatable condition largely impossible. This could be due to the 
several caveats associated with current tests, which requires 
overnight fasts, multiple clinic visits and the oral glucose 
tolerance test (OGTT) which is labor intensive.
Despite the serious public health implications of HIP, there 
has been no universal definition and no universal standards for 
screening and diagnosis, and a wide variety of methods are 
applied (Guariguata et al., 2014). However, fasting plasma 
glucose (FPG), 1-hour, 2-hour or 3-hour plasma glucose 
following a 75g OGTT, interpreted according to the American 
Diabetes Association (ADA), WHO or the International 
Association of the Diabetes and Pregnancy Study Group (IADPSG) 
criteria are the most commonly used methods (Guariguata et al., 
2014; Meek et al., 2020). Glycated hemoglobin (HbA
1c
) can 
also be used to screen for and diagnose HIP, especially in early 
pregnancy (Goyal et al., 2020). Trimester specific cutoff values 
for HbA
1c
 have recently been proposed (Sánchez-González et al., 
2018), though not widely validated or adopted by international 
guidelines (Sánchez-González et al., 2018).
The aim of this study was to determine the prevalence of HIP 
and its associated risk factors among pregnant women attending 
ANC in Uganda, irrespective of their gestation age, using 
HbA
1c
. Secondarily, we sought to determine an appropriate 
random blood sugar (RBS) cutoff value for screening for HIP in 
our setting.
Methods
Study design and setting
We conducted a cross-sectional study in a large specialized 
obstetrics and gynecology national referral hospital in Kampala, 
Uganda in September 2020.
This study enrolled pregnant women attending the ANC clinic 
at the directorate of Obstetrics and Gynecology at Kawempe 
National Referral Hospital (KNRH), which also serves as the 
academic teaching hospital for Makerere University College of 
Health Sciences. KNRH was purposively selected due to its 
central location attracting a large number of patients from 
Kampala and its surrounding districts, thus representing the 
demographics of both urban and peri-urban patient populations. 
On average, about 50-60 mothers attend the ANC clinic at 
KNRH from Tuesday to Thursday every week.
Study population
Eligible participants were all pregnant women attending ANC 
(regardless of gestation age) during the study period who 
provided informed consent to participate in the study. Pregnant 
women known to be living with diabetes or haemoglobin-
opathies were excluded. In addition, patients with anemia 
(hemoglobin <11g/dl) were excluded at analysis.
Sample size and sampling procedure
With an estimated prevalence of HIP at 15.6% in Uganda 
(Kiiza et al., 2020), using the formula for the determination of 
sample size for prevalence studies (Kish-Leslie) (Kish, 1965), 
with an assumed non-response rate of 10%, precision of 5%, 
and a Z-score of 1.96 at 95% confidence interval, a sample size 
of 217 was anticipated. Eligible participants were identified, 
and consecutively sampled with the assistance of a senior nurse 
at the ANC clinic and two other trained study nurses.
Data collection
Study clinicians administered a semi-structured study question-
naire through a face-to-face interview to collect information 
regarding risk factors and symptoms for HIP and maternal 
characteristics: age, gravidity, education level, occupation, mari-
tal status, HIV status, tuberculosis contact, gestation age, history 
of abortion, smoking and alcohol usage, and the number of ANC 
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visits in the current pregnancy. Gestation age was estimated 
using the date of the last normal menstrual period. Polyuria, 
polydipsia, and polyphagia were considered classic symptoms of 
diabetes.
Diagnosis of hyperglycemia in pregnancy. All consenting 
mothers were subjected to a RBS and HbA
1c
 tests. RBS was 
performed at the point of care on venous blood samples using 
the On-CallTM Plus Glucometer (ACON Biotech, China) 
according to manufacturer’s instruction. HbA
1C
 was estimated 
using Cobas® 6000 analyzer series (Roche Diagnostics) at the 
Central Diagnostic Laboratory Services (CDLS), Medical 
Research Council/Uganda Virus Research Institute and London 
School of Hygiene and Tropical Medicine Uganda Research 
Unit laboratory within 24 hours of sample collection. Predia-
betes was defined as HbA
1c 
of 5.7% to 6.4% and overt diabetes 
(diabetes in pregnancy, DIP) as HbA
1c 
of 6.5% or higher, accord-
ing to the American Diabetes Association (Goyal et al., 2020) 
and consistent with guidelines of the IADPSG (Meek et al., 
2020; Saravanan et al., 2020), and the WHO classification of 
hyperglycemia first diagnosed in pregnancy (WHO, 2018). 
Patients with HIP were referred for the appropriate clinical care 
according to the national guidelines.
Complete blood count. A complete blood count was performed 
using the HumaCount 5D Hematology System (Wiesbaden, 
Germany) using 3 mL of blood samples collected in EDTA 
tubes within 12 hours from the time of sample collection. 
Patients with hemoglobin concentration of 11g/dl or lower 
were regarded as having anemia according to the WHO defini-
tion (World Health Organization, 2011) of anemia in pregnancy 
and were subsequently excluded from the study at analysis. 
Anemic patients were also referred for appropriate management 
by the clinical team.
Anthropometrical assessment. Weight was measured with 
minimal clothing and without shoes using a digital bathroom 
weighing scale (SECA-Germany), placed on a flat surface 
and recorded to the nearest 0.1kg. Height was measured using 
a calibrated stadiometer. Waist and hip circumferences were 
measured using a tailor’s measuring tape to the nearest 0.1 cm. 
Body mass index and Waist-Hip Ratios were calculated 
accordingly. Brachial blood pressure was measured from both 
arms while mothers were sitting down with their feet flat on 
the ground using an automated machine with an appropriate 
adult cuff size. The average of the two measurements was 
considered as the participant’s blood pressure. Women were 
classified as hypertensive if systolic and diastolic blood 
pressure were ≥140mmHg and ≥90mmHg, respectively, and 
normal if blood pressure is less than 140/90mmHg.
Statistical analysis
Statistical analyses were performed using STATA version 16 
(StataCorp LLC, College Station, TX, USA) and GraphPad 
Prism version 8.0.4 (GraphPad Software, La Jolla, CA, USA). 
The data were expressed as absolute numbers and percent-
ages for categorical variables, and as means and standard 
deviations (mean ± SDs) for continuous variables. Shapiro-Wilk 
normality test was applied to evaluate all quantitative variables 
to select the appropriate test. Welch’s One-Way ANOVA was 
used to compare continuous data across groups. Chi-square or 
Fisher’ Exact tests were used to assess associations between HIP 
across demographic and clinical characteristics of participants. 
Variables with a p value <0.2 were fitted into a multivariable 
logistic regression model to adjust for confounders. Receiver 
operating characteristics (ROC) curve analysis was performed 
to determine the optimum cutoff of RBS in those patients who 
met criteria for HIP in relation to HbA
1c
 test. Area under the 
ROC curve (AUC) was shown with 95% Wilson confidence 
intervals (CI). Optimal diagnostic cut-off value for RBS were 
calculated using Youden’s J statistic (sensitivity+specificity-1). 
For this analysis, the hypothesis was that at the optimal RBS 
cut off, the AUC = 0.7. In all analyses, P<0.05 was considered 
significant at 95% CI.
Ethical considerations
This study was approved by the Makerere University School 
of Medicine Ethics and Research Committee (reference 
number #REC REF 2020-113). All mothers provided informed 
written consent to participate after the study procedure, risks and 
benefits were explained to them.
Results
In September 2020, a total of 267 pregnant women participated 
in the study. However, 43 participants were excluded due to 
either incomplete data or presence of anemia (Figure 1).
Baseline characteristics of study participants
Of the 224 eligible participants, most were married (91.1%, 
n=204), and attending ANC for the first time in the current 
Figure 1. Study flow diagram.
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pregnancy (63.4%, n=142). Over three quarters had attended 
post-primary education (77.7%, n=174) and were business-
women (42.2%, n=99). The mean age of the women was 26 years 
(SD± 5), of which 138 (61.6%) were ≥25 years old. Just over 
one-third of the participants were primigravida (34.8%, n=78), 
and the majority of the mothers were in their 2nd or 3rd trimes-
ter of pregnancy (94.6%, n=212), with a mean gestation age of 
26.6 weeks (SD ± 7.3) (Table 1). In total, 43 (19.2%) women 
had at least one of the classic symptoms of diabetes.
Table 1. Sociodemographic and maternal characteristics 
of the study participants.
Participant variable N (%) or Mean ± SD
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Participant variable N (%) or Mean ± SD























 was performed for all the 224 participants. The 
median (range) RBS was 4.6 (2.8-8.0) mmol/l. The median 
(range) of HbA
1c
 was 5.2 (3.6-14.9).
The overall prevalence of HIP was 11.2% (n=25) (95% 
CI: 7.7-16.0); 2.2% (n=5) (95% CI: 1.0-5.1) had DIP, and 
8.9% (n=20) (95% CI: 5.9-13.4) prediabetes using the WHO 
criteria. Patients with HIP were slightly older than those 
without (28 years vs. 26 years, p=0.027), had previous tubercu-
losis contact (24% vs. 6.5%, p=0.003), had a bigger hip circum-
ference (107.8 (±10.4) vs. 103.3 (±9.7) cm, p = 0.032) and a 
higher proportion of urban dwellers had HIP compared to their 
rural counterparts (88% vs.69.8%), though this was not statisti-
cally significant (p=0.062) (Table 2). However, after accounting 
for important confounders in a multivariable logistic regression 
models, none of these factors showed a statistically significant 
association (Table 3).
The mean RBS was slightly higher in those with HIP compared 
to those with normal HbA
1c




 as a reference variable, ROC curve and the AUC 
for RBS as a predictor of HIP was 0.75 (95% CI: 0.70-0.80, 
Table 2. Prevalence of hyperglycemia among pregnant 
women at Kawempe National Referral Hospital.
Participant variable HIP (n=25) No HIP 
(n=199)
P-value
N (%) N (%) 
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Participant variable HIP (n=25) No HIP 
(n=199)
P-value
















































Participant variable HIP (n=25) No HIP 
(n=199)
P-value
N (%) N (%) 
Anthropometry, mean 
± SD
Weight (kilograms) 71.4 ± 15.0 68.6 ± 12.0 0.274
Height (meters) 1.6 ± 0.07 1.6 ± 0.06 0.408









Waist-hip circumference 0.92 ± 0.08 0.92 ± 0.08 0.327












Table 3. A multivariable logistic regression model showing 
factors associated with hyperglycemia among pregnant 






Age 1.04 0.92 - 1.16 0.549
District of residence
Entebbe 1.00  
Kampala 1.55 0.49 - 4.92 0.458
Mukono 9.36 0.6 - 146.93 0.112
Residence
Rural 1.00  
Urban 3.80 0.92 - 15.63 0.064
BCG scar
Yes 1.00  
No 1.72 0.64 - 4.58 0.280
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Yes 4.14 1.23 - 13.98 0.022
Gravidity
Primigravida 1.00  
Multigravida 1.67 0.43 - 6.43 0.458
Grand multigravida 2.08 0.3 - 14.55 0.462
Great grand multigravida 4.01 0.28 - 56.64 0.304
Previous abortion
No 1.00  
Yes 1.24 0.37 - 4.21 0.728
Body mass index 0.98 0.84 - 1.15 0.826
Hip circumference 1.06 0.98 - 1.14 0.132
CI, confidence interval.
Figure 2. Random blood sugar levels across different glycemic 
status.
p<0.001) (Figure 3). We derived optimum cutoffs for RBS of 
4.75 mmol/L with a sensitivity and specificity of 90.7% and 
56.4%, respectively. At a lower RBS cutoff of 4.0 mmol/L, the 
sensitivity and specificity was 99.5% and 23.6%, respectively, 
and at a higher RBS cutoff of 5.5 mmol/L, the sensitivity and 
specificity was 26.9% and 83.5%, respectively.
Discussion
The use of HbA
1c
 for screening, diagnosis and monitoring of 
diabetes and prediabetes in pregnancy remains a work in progress 
with several unanswered questions (Hughes et al., 2016). In 
the present study, we aimed to determine the prevalence and 
factors associated with HIP using HbA
1c
 in Uganda. To our 
knowledge, this is the first study to report on the use of HbA
1c
 
to screen for HIP in Uganda. In our study, the prevalence of HIP 
ranged between 7.5 and 16.0%. This is consistent with the 
estimated prevalence of HIP of 16% reported in the Africa 
region (Guariguata et al., 2014). In two previously published 
studies from Uganda, the prevalence of HIP was 15.6% using 
FPG criteria (Kiiza et al., 2020) and 31.9% using OGTT criteria 
(Nakabuye et al., 2017). The observed differences in the 
prevalence of HIP across these studies could be due to the 
difference in the diagnostic criteria used. It is well established 
that due to physiological changes in pregnancy, HbA
1c
 level 
decreases as gestation age increases (Kumpatla et al., 2013; 
Rafat & Ahmad, 2012; Schaible et al., 2018). This could explain 
the low prevalence observed in our study.
HIP is typically diagnosed between 24th and 28th weeks of 
gestation (WHO, 2018). However, evidence from the metacentric 
landmark trial, hyperglycemia and adverse pregnancy outcome 
(HAPO) showed that continued exposure to hyperglycemia 
Figure 3. Receiver operating characteristic curve.
non-diagnostic for diabetes was associated with adverse 
maternal and fetal outcomes (Catalano et al., 2012; HAPO 
Study Cooperative Research Group et al., 2008). Based 
on this finding, current guidelines recommend early 
screening and appropriate management of HIP to improve 
maternal and fetal outcomes (WHO, 2018). OGTT is generally 
considered the gold standard for screening for HIP (Coetzee 
et al., 2020). However, FPG and HbA
1c
 can also be used. HbA
1c
 
has been shown to correlate with poor maternal-fetal outcomes 
(Ho et al., 2017). Studies to establish normal HbA
1c
 reference 
ranges in pregnancy are scarce. Among healthy non-diabetic 
pregnant women, a recent study from Mexico has shown 
that the upper limit of HbA
1c
 increases with gestation age 
(Sánchez-González et al., 2018). In this population, the cutoff 
for the diagnosis of HIP was nearly identical to the American 
Diabetes Association criteria for the diagnosis of diabetes and 
prediabetes in non-pregnant population and in early pregnancy. 
However, given the ease of HbA
1c
 compared to OGTT, testing 
may improve follow-up rates and combining HbA
1c
 analysis with 
FPG or waist circumference may improve detection rates 
(Hughes et al., 2016).
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Risk factors for HIP include advancing age; obesity; exces-
sive weight gain during pregnancy; a family history of diabetes; 
HIP during a previous pregnancy; a history of stillbirth or infant 
with congenital abnormality; and glycosuria during pregnancy 
significantly overlap with those of type 2 diabetes mellitus 
(Diabetes Canada Clinical Practice Guidelines Expert Com-
mittee et al., 2018; Farrar, 2016; Saravanan et al., 2020). In 
our study, the majority of the patients were young, and family 
history of diabetes was only elicited in 20% of the patients. 
This is consistent with published studies in Uganda and 
elsewhere that have reported that over one-third to half of 
mothers do not have known risk factors (Nakabuye et al., 2017; 
Thacker & Petkewicz, 2009). This has implications for the 
selection of patients for screening. RBS has been studied as a 
possible screening tool. It is interesting that none of the patients 
with DIP in our study had RBS above 11.1 mmol/L. In one study 
conducted in Nigeria, using OGTT as a reference standard, the 
best threshold for screening was 5.4 mmol/L for RBS, which had 
a sensitivity of 45% and a specificity of 90.0% (Adefisan et al., 
2020). In our study, with a cutoff of 4.75mmol/L, we found the 
reverse, a higher sensitivity (90.7%) and a lower specificity 
(56.4%). However, at a cutoff of 5.5 mmol/L, we found a simi-
lar diagnostic performance (sensitivity of 27% and specificity 
of 84%). Given the high sensitivity of RBS at a relatively lower 
RBS cutoff and the cost of performing HbA
1c 
especially in 
LMICs, RBS – a cheap and readily available modality – may be 
used alongside HbA
1c
 for screening for HIP in our setting.
Our study is not without limitations. Firstly, we had a small 
sample size derived from a single center and thus our findings 
may not be generalizable to the general population of pregnant 
women in Uganda. Secondly, there is no established HbA
1c
 
reference ranges among Ugandan women stratified by gestation 
age. It is therefore likely that we may have missed some cases 
of HIP since we used HbA
1c
 cutoff for non-/early pregnancy 
population. However, we excluded anemic patients by per-
forming hemoglobin estimation for all mothers. Lastly, being a 
pilot study, we were unable to retrieve key risk factors, such as 
pre-pregnancy weight, and birth weights and perinatal outcomes 
of previous pregnancies. However, over 60% of the mothers 
were primigravida. However, the strength of this study lies in its 
inclusiveness of pregnant mothers of different gestation ages 
from both urban and peri-urban communities. We report for the 
first time the feasibility of screening for HIP using HbA
1c
 in a 
resource limited setting and the utility of RBS as an adjunct to 
HBA
1c
 to aid in identifying of mothers who are likely to have 
HIP.
Conclusions
In conclusion, we found a slightly over 10% prevalence of HIP 
among Uganda women all ages of gestation. The majority of 
those diagnosed with HIP were young without identifiable risk 
factors for hyperglycemia. RBS and HbA
1c
 may be used comple-
mentarily to diagnose HIP in resource constrained settings. We 
recommend a larger, multicenter study using different diagnostic 
modalities to confirm of findings.
Data availability
Underlying data
Figshare: Hyperglycemia in pregnancy diagnosed using glycated 
hemoglobin (HbA1c) in Uganda: a preliminary cross-sectional 
report dataset, https://doi.org/10.6084/m9.figshare.13292690.v1 
(Bongomin, 2020).
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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